Alternatives to insulin glargine
FDA shortage status is active for insulin glargine; 1 same-class SPL records are listed below for registry comparison only.
Brand: Lantus, Basaglar, Toujeo
insulin glargine class peers while FDA lists an active shortage
insulin glargine (Lantus, Basaglar) is on an FDA shortage listing while 1 other Long-Acting Insulin SPL records remain in this registry peer set (class inventory 2). Labeled indication field for insulin glargine: Basaglar is used to lower blood sugar in adults and children with type 1 diabetes.
Top FAERS reaction fields for insulin glargine total 112,926 reports across 10 reactions, set beside insulin detemir. Counts are exposure-weighted submissions, not per-patient risk.
About insulin glargine
Basaglar is a long-acting insulin that helps control blood sugar levels. It is used to treat type 1 and type 2 diabetes.
Used for: Basaglar is used to lower blood sugar in adults and children with type 1 diabetes. It also helps adults with type 2 diabetes manage their blood sugar. However, Basaglar is not for treating diabetic ketoacidosis, a serious condition with high levels of ketones in the blood.
1 Long-Acting Insulin peers (wide set)
insulin glargine vs insulin detemir · FAERS reaction fields
FAERS top-reaction field "Blood Glucose Increased" shows the widest count spread between insulin glargine and insulin detemir in this extract (31,994-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | insulin glargine | insulin detemir |
|---|---|---|
| Blood Glucose Increased | 38,214 | 6,220 |
| Blood Glucose Decreased | 10,314 | 1,568 |
| Inappropriate Schedule Of Product Administration | 9,798 | - |
| Nausea | 9,568 | 1,972 |
| Product Storage Error | 8,531 | - |
| Visual Impairment | 8,514 | - |
| Hypoglycaemia | 7,786 | 1,061 |
| Diarrhoea | 6,900 | 1,399 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
insulin glargine shortage vs Long-Acting Insulin peer index
Shortage status
FDA shortage listing is active for insulin glargine (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for insulin glargine while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for insulin glargine: see also the generic vs brand label guide when reading Lantus SPL strings.
Read our methodology - how this data is sourced, computed, and verified.